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that the KIM has a finite gating threshold and therefore, in 
the presence of motion, it will deviate from the planned 
treatment. 
 
Figure 1. (a) Planned, (b) delivered with KIM gating, and (c) 
simulated delivery without KIM gating correction isodose 
distributions for a fraction of patient 1. Dose levels >95% are 
shown. 
 
Conclusions: The initial results indicate that KIM gating 
improves the agreement between the planned and delivered 
treatments for prostate radiotherapy. A more accurate 
delivery with KIM can facilitate dose escalation and also 
potentially improve treatment outcomes. Future work will 
include investigation of more patients and fraction data, and 
statistical analysis.  
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Purpose/Objective: Kilovoltage Intrafraction Monitoring 
(KIM) is a new real-time IGRT system undergoing first-in-
world clinical use. With KIM, the kV imager is employed while 
the MV beam is on. Radio-opaque markers implanted into the 
target are detected in the kV images, and 2D-to-3D 
reconstruction is performed to compute the 3D target 
position in real-time. The 3D target position is displayed to 
the clinical team during treatment and is used to make 
guidance decisions. KIM has shown sub-millimetre accuracy 
from phantom experiments and retrospective prostate and 
liver cancer patient studies. However to date there have 
been no prospective patient results where KIM is employed in 
real-time to make guidance decisions. We report the 
accuracy measurements from the first prospective clinical 
trial of KIM for prostate cancer VMAT patients. 
Materials and Methods: Simultaneous intratreatment kV and 
MV images of the 52 fractions from the three prostate cancer 
patients treated with KIM real-time guidance to date were 
acquired. For each treatment fraction the KIM real-time 
measurements of the prostate implanted marker positions 
were compared to retrospectively measured kV-MV 
triangulated marker positions. The kV-MV triangulated 
positions were considered to be the ground truth. The mean 
and standard deviation of the measured position differences 
between KIM and kV-MV triangulation in the left-right (LR), 
superior-inferior (SI) and anterior-posterior (AP) directions 
were recorded and analysed. Due to the VMAT MLC 
modulation, the markers were not visible in all MV images, 
however at least one marker was visible in 6461 (of 47320 
total) images, with the number of images available for 
analysis in any one fraction ranging from 66 to 167. 
Results: The mean error of KIM in the LR, SI and AP directions 
was 0.17, 0.55, and -0.61 mm respectively, with standard 
deviations of 0.56, 0.29 and 0.48 mm respectively. The 
accuracy results for each fraction of each patient are shown 
in the figure. The accuracy and precision are both sub-
millimetre. The results across the fractions and patients are 
quite similar, indicating that further improvements to the 
accuracy could be performed to reduce the residual small 
systematic accuracy error. 
 
 
Conclusions: A new real-time tumour position monitoring 
system, Kilovoltage Intrafraction Monitoring (KIM), has been 
clinically implemented and demonstrated to have sub-
millimetre accuracy and precision in the results to date. As 
KIM is implemented on a standard linear accelerator with 
little modification, this accurate technology can potentially 
be widely used on existing cancer radiotherapy systems.  
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Purpose/Objective: Radiotherapy treatment for breast 
cancer increases the risk of major coronary events1, with 
dose received by the Left Anterior Descending (LAD) coronary 
artery an area of particular concern2. Deep inspiration 
breath-hold (DIBH) is demonstrated as an effective method to 
reduce cardiac doses during breast irradiation3. Following its 
implementation across our centres a reduction of mean heart 
dose was observed for left sided breast radiotherapy. This 
study will further investigate these changes in cardiac dose 
and explore LAD mean and maximum doses. 
Materials and Methods: This retrospective study investigated 
275 left-sided breast cancer patients treated with DIBH 
